Feline restrictive orbital myofibroblastic sarcoma treated with toceranib phosphate (Palladia) as adjuvant chemotherapy: A case study of one cat

KEY CLINICAL MESSAGE: This is the first case report of treatment with toceranib phosphate as postsurgical adjuvant chemotherapy for advanced FROMS. This reported case highlights the need for further studies on the efficacy of toceranib phosphate as adjuvant chemotherapy for FROMS. ABSTRACT: Feline r...

Descripción completa

Detalles Bibliográficos
Autores principales: Komatsu, Hiroyuki, Ueshima, Asuka, Kobayashi, Yoshitaka, Shimoyama, Yumiko, Takiyama, Naoaki, Rimpo, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276202/
https://www.ncbi.nlm.nih.gov/pubmed/37334334
http://dx.doi.org/10.1002/ccr3.7582
Descripción
Sumario:KEY CLINICAL MESSAGE: This is the first case report of treatment with toceranib phosphate as postsurgical adjuvant chemotherapy for advanced FROMS. This reported case highlights the need for further studies on the efficacy of toceranib phosphate as adjuvant chemotherapy for FROMS. ABSTRACT: Feline restrictive orbital myofibroblastic sarcoma (FROMS) is a rare aggressive tumor in cats. We explored the effectiveness of using toceranib phosphate as postsurgical adjuvant chemotherapy for advanced FROMS in a 7‐year‐old cat. Despite treatment, the cat died 4 months after surgery. This report highlights the need for further studies on the efficacy of toceranib phosphate as adjuvant chemotherapy for FROMS.

Ejemplares similares